Insilico Medicine’s ISM8969 Enters Phase 1 Trial, Advancing Brain-Penetrant NLRP3 Inhibitor for Neuroinflammation and CNS Disorders

Insilico Medicine has announced a major clinical milestone for ISM8969. The company confirmed completion of first-in-human dosing in a Phase 1 study. This study is conducted in collaboration with Hygtia Therapeutics. ISM8969 is an oral, brain-penetrant NLRP3 inflammasome inhibitor. It targets chronic neuroinflammation and CNS disorders including Parkinson’s disease.

ISM8969 Launches with First-in-Human Dosing and CSF Sampling

The Phase 1 trial is randomized, double-blind, and placebo-controlled. It includes single ascending dose and multiple ascending dose cohorts. The study evaluates safety, tolerability, pharmacokinetics, and pharmacodynamics. It enrolls healthy participants and obese adults at cardiovascular risk. The trial is conducted in Australia with 100 total participants planned.

Researchers will also collect cerebrospinal fluid samples. These samples assess CNS penetration and target engagement. The data will guide dose selection in later trials. It will also support future therapeutic validation in neurodegenerative disease programs.

NLRP3 Inhibition Targets Neuroinflammation and CNS Disease Progression

ISM8969 targets the NLRP3 inflammasome, a key innate immune regulator. Overactivation of NLRP3 drives chronic inflammation and cytokine release. This process contributes to neurodegeneration and tissue damage. The mechanism is linked to diseases such as Parkinson’s disease.

The candidate is designed as a brain-penetrant small molecule. It differentiates from peripherally restricted NLRP3 inhibitors in development. CNS exposure enables direct modulation of neuroinflammation. This creates potential for broader neurological disease applications.

Preclinical studies showed strong in vitro activity and favorable safety. The molecule demonstrated consistent in vivo pharmacokinetics and pharmacodynamics. It also showed efficacy in multiple inflammatory disease models. These included both acute and chronic preclinical systems. ISM8969 was selected as a preclinical candidate in December 2024.

AI-Driven Drug Discovery Powers Insilico Medicine’s Development Strategy

“Advancing ISM8969 from an AI-generated concept to first-in-human dosing is a major step forward, as well as the first clinical milestone in our collaboration with Hygtia Therapeutics,” said Feng Ren, PhD, Co-CEO and Chief Scientific Officer of Insilico Medicine.

“Developing an effective NLRP3 inhibitor that can safely penetrate the blood-brain barrier has long been a challenge for the industry. Leveraging Chemistry42, we precisely optimized the molecule to deliver strong preclinical efficacy and favorable permeability. We look forward to evaluating its translational potential in this Phase 1 trial and to continuing our close collaboration with Hygtia to advance innovative neuroscience therapies for patients worldwide.”

The companies formed an exclusive global co-development partnership for ISM8969. Both parties hold equal global rights at fifty percent. Insilico leads IND submission and Phase 1 execution. The program may generate up to sixty-six million dollars in milestone payments.

Insilico continues to scale its AI-driven discovery platform. The company shortens preclinical timelines to as low as 12 to 18 months. It also reduces synthesis scale to under 200 molecules per program. Since 2021, Insilico has nominated 31 preclinical candidates. Thirteen have already reached IND approval or clearance.

The company also advances its MMAI Gym platform for AI benchmarking. This system supports domain-specific scientific model training. It also evaluates real-world pharmaceutical reasoning performance. Partners include Human Longevity and Liquid AI. The platform aims to accelerate progress toward pharma superintelligence.

Author

Steven Chung

紅杏枝頭春意鬧固然是眾人所追求的風景，但我願意說，青蘿拂行衣更能湧生感嘆。 願在海量晦澀的生醫資訊中，為您點亮一座心燈塔。鐘煌翔